This report provides exclusive insights into the COVID-19 impact on the Cancer Immunotherapy Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Cancer Immunotherapy Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Cancer Immunotherapy Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by
Infinium Global Research on cancer immunotherapy market provides in-depth
analysis of segments and sub-segments in the global as well as regional cancer
immunotherapy market. The study also highlights the impact of drivers,
restraints, and macro indicators on the global and regional cancer
immunotherapy market over the short term as well as long term. The report is a
comprehensive presentation of trends, forecast and dollar values of global
cancer immunotherapy market. According to the report, the global cancer
immunotherapy market is projected to grow at a CAGR of 15.12% over the forecast
period of 2019-2025.
Market Insight
Cancer immunotherapy is defined as
the artificial stimulation of the immune system to treat cancer. It improves the natural ability of the system
to fight against cancer and also improves the immunity of abolishing the cancer
cells. To slow down the growth of cancer cells and stop spreading of cancer
this therapy is given to cancer patients. These immunotherapy uses to modulate
the immune system of patients, which improve the activity of the immune system
to fight against tumors. these therapies are designed to perform as immune
stimulating agents that improve the responses against tumor cells.
Increasing incidents of cancers
are the major factor driving the growth of the cancer immunotherapy market. As
per the WHO, cancer is the second cause of death all over the world. Owing to
smoking, alcoholism and inactive lifestyle the incidences of cancer is
increasing. And this factor upsurges the number of cancer population resulting
in the growing demand for cancer immunotherapy market. As per the new global
cancer date, the cancer burden has increased up to 18.1 million cases and 9.6
million cancer deaths. Further, an estimate as per the National Cancer
Institute in 2018, 1,735,350 new cases of cancer were diagnosed in the U.S and 609,640
people died due to the diseases. Further, advancement in cancer therapies,
increasing investments in R&D activities, and growth in healthcare
expenditure is also boosting the market growth. On the contrary, the lack of
skilled healthcare professionals in this field restrains the growth of the
market. Besides, increasing awareness about this therapy among consumers is
gaining significant growth opportunity in the upcoming year.
As per the geographies, North
America accounted for the largest market share for the cancer immunotherapy
market followed by Europe and Asia Pacific region. In North America region
growing numbers of patients, growing investments in R&D activities by the
governments are some of the major factors driving the growth of cancer immunotherapy
market in this region. In the Europe region, increasing income of an
individuals and accessibility of cancer immunotherapy drugs motivates the
growth of the market. Further, Asia Pacific region is anticipated to grow at
the fastest rate due to factors such as growing incidents of cancer, and
growing government investments on medical infrastructure are boosting factors
for the growth of cancer immunotherapy market in Asia Pacific region.

Segment Covered
The report on global cancer
immunotherapy market covers segments such as therapeutic area, therapy type,
and end users. On the basis of the therapeutic area, the sub-markets include lung
cancer, melanoma, breast cancer, colorectal cancer, blood cancer, and prostate
cancer. On the basis of therapy type, the sub-markets include monoclonal
antibodies, immune system modulators, immune checkpoint inhibitors, and cancer
vaccines. On the basis of end users, the sub-markets include hospitals,
ambulatory surgical centers, clinics, and cancer research centers.
Companies Profiled:
The report provides profiles of
the companies in the market such as GlaxoSmithKline plc., AstraZeneca plc, Merck & Co., Inc., Immunomedics, Inc., F. Hoffmann-La Roche AG, Eli
Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Amgen, Inc., and Novartis International AG.
Report Highlights:
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of the cancer immunotherapy market. Moreover, the study highlights current
market trends and provides forecast from 2019-2025. We also have highlighted
future trends in the market that will affect the demand during the forecast
period. Moreover, the competitive analysis given in each regional market brings
an insight into the market share of the leading players.